US-based biopharmaceutical firm Loxo Oncology has entered into a collaboration agreement with Ventana Medical Systems, a division of Switzerland-based healthcare company Roche, to develop and commercialise a companion diagnostic test for experimental drug larotrectinib (LOXO-101).

The diagnostic pan-tropomyosin receptor kinase (TRK) immunohistochemistry (IHC) test will be utilised for the identification of patients across tumour types who can be treated with larotrectinib.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Larotrectinib  is a potent, oral and selective investigational new drug being developed to treat patients with cancers that include abnormalities involving the TRKs.

"The diagnostic assay will be optimised and validated to ensure its ability to withstand clinical and regulatory scrutiny."

An investigational assay piloted by Loxo Oncology will be further developed by Roche using the latters OptiView DAB detection technology.

Loxo Oncology chief executive officer Josh Bilenker said: "Our initial technology assessment suggests that an IHC pan-TRK assay is feasible, which is exciting since Roche has thousands of Ventana BenchMark instruments installed worldwide.

See Also:

"Diagnostics are a crucial part of our commercial strategy, and we believe IHC will be an important tool, alongside next-generation sequencing, that pathologists can employ in screening for patients who may benefit from larotrectinib.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The diagnostic assay will be optimised and validated to ensure its ability to withstand clinical and regulatory scrutiny.

The firms intend to intially commercialise an analytical assay and later develop a class III assay for pre-market approval (PMA) from the US Food and Drug Administration (FDA).

Roche will develop, obtain and maintain regulatory approvals for the companion diagnostic test in the US, certain countries in the EU and other countries that accept the CE / in-vitro diagnostic registration process.